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Abstract
Objective: To analyse the associations between chronic respiratory diseases and
intakes of total flavonoids and their major subclasses (flavanones, anthocyanins,
flavan-3-ols, flavonols, flavones, polymers and proanthocyanidins).
Design: Multi-case–control study.
Setting: The analysis was conducted in the frame of the Genes Environment
Interaction in Respiratory Diseases (GEIRD) study. The European Prospective
Investigation into Cancer and Nutrition FFQ was used to ascertain dietary intake.
Multinomial regression models adjusting for age, sex, centre, BMI, smoking habit,
alcohol intake, education, total energy intake, vitamin C intake and total fruit intake
were used to examine the associations between dietary exposures and the relative
risk ratio (RRR) of being a case.
Participants: Individuals (n 990) hierarchically defined as follows: cases with
asthma (current, n 159; past, n 78), chronic bronchitis (n 47), rhinitis (allergic
rhinitis, n 167; non-allergic rhinitis, n 142) and controls (n 97).
Results: An increase of 1 SD in flavanones was associated with a reduced risk of
non-allergic rhinitis (adjusted RRR = 0·68, 95 % CI 0·47, 0·97); a similar result
was found comparing the highest v. lowest quartile of flavanones intake (adjusted
RRR= 0·24, 95 % CI 0·10, 0·59).
Conclusions: Flavonoids contained in fruits and vegetables, especially flavanones,
might reduce the risk of non-allergic rhinitis. No associations were found between
other flavonoids and the considered outcomes.
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Chronic inflammation in the airways is a central feature
in asthma and other respiratory diseases and is mostly
driven by oxidative stress(1,2). The imbalance between
endogenous oxidant and antioxidant substances can be
influenced by diet, in particular fruits and vegetables,
which are rich in antioxidants. Epidemiological evidence
suggests that a diet rich in these foods might have a benefi-
cial effect on asthma and lung function in adults and
children(1,3–6).
Extensive experimental evidence shows that flavo-
noids, which are polyphenols synthesized by plants,
have antioxidant, anti-allergic and anti-inflammatory
effects(7–13). It is known that flavonoids can reduce the acti-
vation of the cyclooxygenase gene, which is involved in the
inflammatory response(14,15), and theymight act as an inhibi-
tor of lipoxygenase, whose products are involved in the
pathogenesis of a series of inflammatory diseases, including
rhinitis(16). Lipoxygenase uses peroxyl radical complexes
for the metabolism of arachidonic acid and flavonoids
might act as antioxidants by neutralizing the radicals(17).
In spite of the extensive and promising experimental
evidence suggesting a potential benefit of flavonoids on
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airways disease, epidemiological studies examining this
association are still scant and limited to few flavonoid
subclasses(18). In Finnish adults, higher intakes of querce-
tin, naringenin and hesperetin were associated with a
reduced risk of asthma(19). In a case–control study con-
ducted in London, dietary intake of three major flavonoids
(catechins, flavonols and flavones) was not associated with
asthma or chronic bronchitis(20).
GEIRD (Genes Environment Interaction in Respiratory
Diseases), a population-based multi-case–control study,
aimed to provide evidence on environmental exposures,
history of disease, treatment, genetic information and
measurements of markers of inflammation in individuals
affected by asthma, allergic rhinitis and chronic obstructive
pulmonary disease (COPD)(21). In this population, we
investigated the association of dietary intake of six major
classes of flavonoids and risk of asthma, chronic bronchitis
and rhinitis.
Materials and methods
Study design
GEIRD, a population-based multi-case–control study, is a
two-stage project which involves seven Italian centres(21).
The first stage aimed to find probable cases and controls
through a screening questionnaire on respiratory symp-
toms. The questionnairewasmailed to pre-existing random
cohorts (the Italian Study on Asthma in Young Adults
(ISAYA)(22), the Italian arm of the European Community
Respiratory Health Survey (ECRHS-Italy)(23)) and a new
random sample from the general population (20–84 years
of age, male/female = 1/1). The second stage aimed to
ascertain the respiratory condition of the individuals
through a clinical visit. Individuals invited to clinics were
a random sample of those who reported signs suggestive
of rhinitis and those free from any respiratory symptoms,
and all individuals who reported signs suggestive of
chronic bronchitis (CB), COPD or asthma. In this stage,
each individual underwent a computer-assisted clinical
interview, lung function tests, reversibility test, methacho-
line test and skin prick test (SPT), and dietary information
was collected through a self-administered FFQ. All mea-
surement protocols agreed with international guidelines
(www.geird.org)(21). In the present analysis, only the
individuals with information on the FFQ recruited in the
years from 2007 to 2010 in the centres of Pavia, Torino,
Sassari and Verona were considered.
Lung function and allergological tests
All outcome variables were assessed following standard
procedures that included previously validated spirometric
tests. Individuals underwent spirometry for forced
expiratory volume in the first second (FEV1) and forced
vital capacity (FVC), measured according to the American
Thoracic Society reproducibility criteria(24). FEV1 % predicted
and the lower limit of normal (LLN) for the
FEV1/FEC were calculated on the basis of Quanjer et al.’s
equations(25). Individuals with a FEV1/FVC≥ 70% and
≥LLN underwent a methacholine challenge test, which
followed a protocol described elsewhere(26). Individuals
with a FEV1/FVC< 70% or <LLN underwent a bronchodila-
tor challenge test and were invited (if eligible) to undergo a
methacholine challenge test on a second occasion. Atopy
was assessed by SPT to common allergens(27).
Dietary exposure assessment: flavonoid intake
estimates
All exposure measurements were assessed following
standard procedures that included previously validated
questionnaires. Information on dietary intakewas collected
using the Italian version of the validated European
Prospective Investigation into Cancer and Nutrition
(EPIC) FFQ, which was based on Italian dietary habits
and developed in the frame of an international survey(28).
The NAF (Nutritional Analysis of Food Frequency
Questionnaires, National Cancer Institute, Milan, Italy)
software(29) was used to compute the daily intakes of
food items, energy, macro- and micronutrients. Nutrient
data for specific foods were obtained from the food com-
position database for epidemiological studies in Italy(30).
Information on flavonoid intake was derived from the
foods contained in the FFQ (mostly plant-derived).
Estimates for intakes of total flavonoids and seven major
subclasses (flavanones, anthocyanins, flavan-3-ols, flavo-
nols, flavones, polymers and proanthocyanidins),
expressed as aglycones (mg/d), were derived from sixty-
five foods (see online supplementary material,
Supplemental Table S1) using the US Department of
Agriculture’s updated and expanded flavonoid content of
foods and proanthocyanidin databases(31,32).
Overall, out of the 2749 individuals participating in the
clinical stage of the survey, 1182 (43 %) filled in the FFQ.
Forty-three individuals with incomplete FFQ (less than
80 % of the 434 questions and nested questions of the
FFQ filled in) were excluded from the analyses. We
estimated BMR using sex-specific equations for adults
(≤60 years old)(33) and the elderly (>60 years old)(34).
Twenty-four individuals were excluded as BMR could
not be computed due tomissing data. Individuals were also
excluded if they had extreme values of total energy intake
(EI), which might suggest an unrealistic response: we
excluded those with a ratio of EI to expected BMR below
the 0·5th sample centile or above the 99·5th sample
centile. Eight individuals were excluded according to
the cut-off points on the top (four persons) and bottom
(four persons) 0·5th percentile of the distribution of EI:
BMR. Ten individuals (five women and five men) with
extremely low EI levels (<2510 kJ (<600 kcal) for women
and 3347 kJ (<800 kcal) for men) were excluded from
the analyses(35) (Fig. 1).
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Identification of cases and controls in clinics
The sample for the current analysis included 1097
individuals (Fig. 1) with information on the clinical visit
and on food and nutrient intakes, who were hierarchically
classified as follows.
1. One hundred and fifty-nine cases of current asthma
(CA):
a. he/she reported a history of asthma AND
asthma-like symptoms/medicines in the last 12
months;
b. he/she reported a history of asthma OR asthma-
like symptoms/medicines in the last 12 months
plus one of the following conditions: (i) he/she
had a positive methacholine challenge test with
a provocative dose of methacholine causing a
20 % drop in FEV1 (PD20) of <1 mg; (ii) he/she
had pre-bronchodilator FEV1/FEC< 70 % or
<LLN(25) with a positive reversibility test (i.e.
FEV1> 12 % and >200 ml after the administration
of 400 μg salbutamol); (iii) he/she had pre-
bronchodilator FEV1/FEC< 70 % or <LLN with
a post-bronchodilator FEV1/FVC> LLN and
>70 % and a post-bronchodilator FEV1> 80 %
predicted(25).
2. Seventy-eight cases of past asthma (PA): he/she
reported a history of asthma but did not fulfil the
criteria for CA.
3. Ten cases of COPD: post-bronchodilator FEV1/
FEC< 70 % or <LLN without asthma.
4. Forty-seven cases of CB: he/she was not a COPD or
asthma case and he/she reported chronic cough or
phlegm (>3 months/year for at least 2 years).
5. One hundred and sixty-seven cases of allergic rhinitis
(AR) and 125 cases of non-allergic rhinitis (NAR):
he/she had nasal allergies or nasal problems in the
presence of animal(s), pollens and/or dust, plus a
negative SPT (NAR) or a positive SPT to at least one
allergen (AR).
6. Three hundred and ninety-seven controls: individuals
without any nasal/respiratory symptoms/conditions
reported in the clinical questionnaire neither in the
clinic nor in the screening questionnaire, who were
not cases and had both (i) pre-bronchodilator
FEV1/FVC > LLN and >70 %; and (ii) FEV1 > 70 %
predicted.
Eligible – Stage 1
Respondents – Stage 2
Eligible – Stage 2
Respondents – Stage 2 Did not fill in EPIC FFQ
18 543
11 616
6011
2749 1567
85
97
10
1182
1097
1000
990
Controls:
397
CA:
159
PA:
78
CB:
47
AR:
167
NAR:
142
Unreliable nutritional data
Undefined case–control status
COPD
Filled in EPIC FFQ
Reliable nutritional data
Defined case–control status
Final sample
Case/control classification
Fig. 1 (colour online) Flowchart of participant selection (EPIC, European Prospective Investigation into Cancer and Nutrition; COPD,
chronic obstructive pulmonary disease; CA, current asthma; PA, past asthma; CB, chronic bronchitis; AR, allergic rhinitis;
NAR, non-allergic rhinitis)
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Ninety-seven individuals were unclassified due to miss-
ing data.
Individuals with COPD and unclassified individuals
were excluded from the present analyses, therefore the
final sample included 990 participants. Due to the hierar-
chical classification, cases of CA and PA could also present
COPD/CB/AR/NAR; cases of CB could present AR/NAR.
Statistical analyses
Participant characteristics were summarized as percent-
ages, or as medians and interquartile ranges (IQR), or
means and standard deviations; flavonoid and food intakes
were summarized as medians and IQR. The χ2 test,
Kruskal–Wallis test and Student’s t test were used to test
differences (α= 0·05), where appropriate. The main expo-
sures of interest (total flavonoids and each subclass) were
considered as continuous variables and analysed for a
variation of one standard deviation. Exposures were also
categorized into quartiles based on the distribution of the
exposure in controls. Quartiles allow the comparison of
extreme groups, such as those with highest and lowest
intakes of nutrients or foods, and are less sensitive to the
effects of outliers than continuous variables. On the other
hand, the estimates of measures of disease risk related to
dietary exposures expressed as continuous variables make
easier the comparison of evidence obtained in different
studies.
To analyse the associations between each flavonoid
class and case–control status, several multinomial logistic
regression models were fitted to the data, using a six-level
variable (CA, PA, CB, AR, NAR, control) as outcome.
Multivariable associations of exposures with case–control
status were expressed by relative risk ratios (RRR; using
control as the reference category) and their 95 %
confidence intervals. Analyses were adjusted for study
sample/cohort (ISAYA, ECRHS-Italy, new random sample),
centre (Verona, Pavia, Torino and Sassari), gender, age,
BMI, education (low= completed before the age of 16
years; high= completed after the age of 16 years) as a
proxy of socio-economic status, smoking habit (never
smoker; past smoker, i.e. not smoking in the last month;
current smoker), alcohol intake (g/d), total energy intake
(kcal/d), vitamin C intake (mg/d) and total fruit intake
(g/d). The analyses were performed using the statistical
software package Stata version 14.2.
Results
Among the groups of cases and controls, we found no
differences in terms of age (overall mean: 50·7 (SD 12·3)
years), gender (overall proportion of males: 48·79 %),
BMI (overall median: 24·7 (IQR 22·3–27·7) kg/m2), physical
activity and educational level (Table 1).
Comparing the characteristics of the individuals
who fulfilled the EPIC FFQ (n 1182) and those who did
not (n 1567), we found that mean age was significantly
higher in the groups of controls, CA and AR among indi-
viduals who fulfilled the questionnaire (51·0 (SD 12·0),
Table 1 General characteristics of the participants: adults from the GEIRD (Genes Environment Interaction in Respiratory Diseases)
population-based multi-case–control study in Pavia, Torino, Sassari and Verona, Italy, 2007–2010
Controls (n 397) CA (n 159) PA (n 78) CB (n 47) AR (n 167) NAR (n 142) P value
Age at the clinical visit (years) 0·726
Mean 51·9 50·5 45·2 49·1 49·7 52·3
SD 12·0 12·6 11·3 13·7 12·5 12·0
Gender (% male) 48·36 49·69 44·87 55·32 52·69 44·37 0·625
Smoking habits (%) 0·013
Non-smoker 53·79 50·31 57·14 44·68 57·49 43·66
Ex-smoker 32·58 27·67 27·27 21·28 26·35 34·51
Current smoker 13·64 22·01 15·58 34·04 16·17 21·83
Drinking habits (%) 0·018
Current drinker 35·10 47·17 37·18 57·45 40·72 41·13
Abstainer 64·03 52·2 62·82 41·30 59·51 56.74
Ex-drinker 1·53 0·63 0·00 2·17 1·23 2·13
Total alcohol (%) 0·023
<5 g/d 6·63 14·47 10·26 10·87 5·52 13·48
5–<15 g/d 17·60 16·98 17·95 19·57 15·95 13·48
15–<30 g/d 6·12 10·06 6·41 13·04 13.50 10·64
30–120 g/d 4·08 5·66 2·56 13·04 4.29 3·55
BMI (kg/m2) 0·692
Median 25·0 24·8 23·9 25·5 24.3 24·6
IQR 22·4–27·7 22·0–27·6 21·9–27·0 22·1–28·6 22·6–27·2 22·2–28·0
Physical activity (%) 0·35
Heavy 5·79 4·40 6·41 10·64 8·98 6·34
Moderate 36·27 35·22 32·05 27·66 41·32 42·25
Light 57·93 60·38 61·54 61·70 49·70 51·41
Education level (% high) 75·95 75·95 87·18 70·21 78·44 68·79 0·056
CA, current asthma; PA, past asthma; CB, chronic bronchitis; AR, allergic rhinitis; NAR, non-allergic rhinitis; IQR, interquartile range.
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50·5 (SD 12·6) and 49·7 (SD 12·5) years, respectively) com-
pared with the individuals who did not (49·7 (SD 12·9),
45·2 (SD 11·8) and 46·9 (SD 12·7) years, respectively; see
online supplementary material, Supplemental Table S2).
Among participants included in the analysis, we found
that smoking habits, drinking habits and alcohol intake
varied significantly across the groups (P= 0·013, 0·018
and 0·023, respectively), with the highest proportion of
drinkers and current smokers in the group affected by CB
(57·45 and 34·04 %, respectively). There were no statistically
significant differences in the intakes of total or subclasses of
flavonoids across the case groups (overall median total
flavonoids intake: 382·1 (IQR 248·8–529·8) mg) and in the
intakes of foods rich in flavonoids (Table 2). Overall
median fruit and vegetable intakes were 289·1 (IQR 191·9–
425·5) g/d and 130·2 (IQR 86·7–194·5) g/d, respectively.
There were no statistically significant differences in the
intakes of total energy intake and vitamin C across the
groups (overall median energy intake: 7988·5 (IQR 6299·0–
10 037·0) kJ/d (1909·3 (IQR 1505·5–2398·9) kcal/d); overall
median vitamin C intake: 117·6 (IQR 82·6–161·9) mg/d).
In the unadjusted continuous regression analyses,
there were no significant associations between any of the
flavonoid subclasses and the outcomes considered
(Table 3). After adjustment, we found that an increase of
1 SD in intake of flavanones, equivalent to 26·1 mg/d,
was associated with a reduced risk of NAR (RRR = 0·68,
95 % CI 0·47, 0·97). Similarly, adjusted analyses exploring
the exposures per quartile showed that those in the highest
v. lowest quartile of flavanone intake had a reduced risk
of NAR (RRR = 0·24, 95 % CI 0·10, 0·59). We found no
consistent evidence of an association between a high
intake of other subclasses of flavonoids and the risk of
any of the other outcomes.
Discussion
In this multi-case–control study of Italian adults from the
general population, we found that having a higher intake
of flavanones was associated with a reduced risk of NAR.
The association was statistically significant when the
groups were examined as the highest v. lowest quartile
of intake andwhen the intakewas analysed as a continuous
exposure.
Flavonoids havebeendescribed tohave anti-inflammatory
and antioxidant properties(7–13). Airway inflammation,
which is exacerbated by oxidative stress(14), is known to
be related to the pathogenesis and worsening of pulmo-
nary diseases(2,36). In our study, we considered asthma,
CB and rhinitis, diseases in which airway inflammation
plays a key role(37). Depending on the severity of asthma,
inflammation can affect the large and small airways(2).
Similarly, in CB, inflammation affects the lumen and the
wall of the airways(38). Experimental studies show that
flavonoids can counteract the oxidative stress and
inflammation caused by environmental insult to the air-
ways. Quercetin, one of the most investigated flavonoids,
has been shown to reduce superoxides and nitric oxide
radicals, which are mediators of inflammation(39,40).
Flavonoids can inhibit themetabolism of arachidonic acid,
which is involved in the production of reactive oxygen
species(10,41). Moreover, they seem to reduce the adhesion
of inflammatory cells(14).
In spite of the large body of experimental evidence
supporting an association of flavonoid intake with respira-
tory diseases, epidemiological studies are still scant and
have reported mixed results, which might partly be
explained by the different types of flavonoids studied(42).
Several population-based studies have suggested that
higher intakes of foods rich in flavonoids (mainly fruits,
vegetables, wine and tea) were associated with a lower risk
of asthma(1,43), although this association has not been
confirmed in other studies(44). The few population-based
studies that have examined the association of flavonoid
intake and airways disease are limited and the evidence
is inconclusive. Tabak et al. reported that a higher intake
of catechins was associated with a lower risk of COPD
and asthma in a population of Dutch adults(45). Garcia
et al. found no evidence of an association of three sub-
classes of flavonoids with asthma or CB in a population-
based case–control study in London(20). Moreover, a
recent clinical trial on both adults and children with poor
asthma control revealed no association between the sup-
plementary use of soya isoflavone and lung function(46).
The recent hypothesis that microbiota might play a role
to protect against inflammation-mediated airways diseases
was investigated in a small sample of twenty-three allergic
individuals(47). The study showed that a higher intake of a
diet rich in phenolic compounds was associated with a
more stable gut microbiota, which might contribute to
the management of allergic conditions through a reduced
inflammation. A recent cohort study reported that a higher
intake of soya genistein was associated with improved lung
function and asthma control in individuals with stable
asthma(48). Evidence from human trials is also limited. A
recent randomized controlled trial found no evidence
that supplementation with soya genistein had any effect
on outcomes of asthma or lung function in adults with
unstable asthma(46), while in an intervention in forty-two
asthmatic adults, a passion fruit puree extract rich in biofla-
vonoids reduced the severity of asthma symptoms(49).
In our study, we found limited evidence to suggest
that flavonoids are associated with airways disease. The
individuals in our population-based study had stable
asthma, CB or AR. It might be possible that the beneficial
effect of flavonoids occurs in cases of greater chronic
airway inflammation, which is usually reduced in stable
patients. We found a statistically significant negative
association of flavanones with non-atopic rhinitis. The
association with atopic rhinitis was also negative in both
approaches used, but not statistically significant. Atopy in
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Table 2 Distribution of the dietary flavonoid, food and nutrient intakes studied, according to case or control status, among adults from the GEIRD (Genes Environment Interaction in Respiratory
Diseases) population-based multi-case–control study in Pavia, Torino, Sassari and Verona, Italy, 2007–2010
Controls (n 397) CA (n 159) PA (n 78) CB (n 47) AR (n 167) NAR (n 142)
P
valueMedian IQR Median IQR Median IQR Median IQR Median IQR Median IQR
Flavonoids (mg/d)
Total flavonoids 381·9 255·1–526·5 388·3 258·4–554·9 380·9 212·1–517·5 374·5 198·5–515·1 365·6 238·2–545·5 394·2 277·4–518·4 0·98
Flavanones 27·3 14·0–45·8 27·1 12·8–43·3 28·1 11·1–36·5 23·2 12·3–38·7 28·0 18·3–40·3 26·7 13·4–38·5 0·75
Anthocyanins 17·3 10·0–28·4 15·7 8·8–27·7 16·6 10·7–24·8 15·4 6·2–25·4 15·9 10·3–25·7 17·8 9·3–28·0 0·92
Flavan-3-ols 45·5 26·7–71·9 46·0 27·7–75·2 48·2 26·7–72·3 42·9 28·2–85·8 46·6 25·4–73·4 47·7 29·2–80·1 0·93
Flavonols 15·9 10·8–21·7 15·1 10·4–20·0 15·1 10·6–21·7 17·0 10·8–23·8 15·2 9·6–21·7 15·8 10·2–20·7 0·86
Flavones 1·9 1·1–2·9 2·0 1·2–3·2 1·9 1·3–2·8 1·9 1·2–2·7 1·9 1·0–2·8 1·9 1·0–3·0 0·94
Polymers 269·4 168·6–370·6 261·3 168·6–403·2 267·7 138·3–380·5 257·7 146·1–350·9 247·7 157·3–377·4 254·6 174·7–370·0 0·98
Proanthocyanidins 293·0 188·6–417·2 295·3 188·2–461·4 293·3 154·2–420·0 292·0 163·0–405·5 279·3 178·0–432·5 289·0 197·3–422·1 0·98
Foods (g/d)
Fruits 302·6 203·0–433·0 288.4 193·3–424·1 275·35 168·8–425·7 211·4 142·6–398·6 290·2 200·1–401·6 280·75 188·6–429·0 0·22
Vegetables 129·0 79·8–195·1 118·6 81·4–190·9 150·95 105·2–232·0 152·1 101·1–196·3 128·7 89·4–182·5 131·05 91·1–195·2 0·18
Chocolate 2·7 0·0–8·6 2·9 0·7–12·8 2·9 0·7–11·4 2·9 1·3–10·3 3·7 0·7–8·6 3·7 0·7–11·4 0·12
Red wine 4·2 0·0–62·5 13·9 0·0–107·1 8·1 0·0–62·5 4·2 0·0–79·4 8·3 0·0–63·5 1·9 0·0–59·5 0·47
White wine 1·4 0·0–26·8 2·1 0·0–41·7 3·5 0·0–35·7 0·5 0·0–26·8 1·0 0·0–26·8 1·0 0·0–26·8 0·74
Tea 10·0 0·0–85·7 5·0 0·0–64·3 10·0 0·0–64·3 15·0 0·0–150 15·0 0·0–85·7 10·0 0·0–150 0·52
Nutrients
Vitamin C (mg/d) 116·3 83·4–162·8 116·9 84·0–156·4 129·3 79·8–167·8 105·3 71·5–151·7 119·4 84·6–164·4 118·9 80·9–165·4 0·84
Total energy intake
(kJ/d)
7849·6 6123·7–9989·3 7666·8 6353·4–9288·9 8986·4 6875·1–10 732·8 8892·3 6377·3–11 621·1 8217·4 6602·4–9699·3 7728·3 6278·9–10 132·8 0·13
Total energy
intake (kcal/d)
1876·1 1463·6–2387·5 1832·4 1518·5–2220·1 2147·8 1643·2–2565·2 2125·3 1524·2–2777·5 1964·0 1578·0–2318·2 1847·1 1500·7–2421·8 0·13
CA, current asthma; PA, past asthma; CB, chronic bronchitis; AR, allergic rhinitis; NAR, non-allergic rhinitis; IQR, interquartile range.
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those affected by rhinitis is defined on the basis of an SPT,
which measures the systemic presence of serum allergen-
specific IgE in allergic individuals. However, it has also
been found in individuals affected by non-atopic rhinitis
that allergen-specific IgE can be found locally in the nasal
mucosa, which is not detectable through an SPT(50).
Flavonoids are thought to inhibit the formation of IgE(9,18)
and this might explain the positive effect found on individ-
uals with non-atopic rhinitis in the present study.
Our study did not confirm an association of any of the
flavonoid subclasses studied with CB, which is in line with
the results reported in an earlier case–control study in the
general population(20). Anthocyanin intake was associated
with a reduced risk of CB, but this did not reach statistical
significance. Although inflammation is a central feature in
CB, it might be possible that avoidance of environmental
pollutants and related environmental insult might be the
best effective way to reduce the risk of this disease(38).
Some observational studies have analysed the associa-
tion between flavonoids and atopic rhinitis. The extract
of French maritime bark, which is rich in flavonoids,
appeared to reduce eye and nasal symptoms, but the
results were limited by the small sample of participants(51).
In another clinical trial, a preventive effect of enzymatically
modified isoquercitrin was found on ocular symptoms, but
not on nasal symptoms(52).
Our study has several strengths. We considered several
chronic respiratory diseases, giving a wide view of the
possible role of flavonoids in different pulmonary health
conditions. Case and control status was assessed in a
two-stage process; first by a screening questionnaire on
symptoms and use of medicines, then through a clinical
visit(21). The EPIC FFQ was validated through comparison
with multiple interviews and the analysis of nitrogen in
urine samples(28). We analysed the associations between
flavonoid intakes and chronic respiratory diseases consid-
ering seven subclasses of flavonoids, computed using data
from the US Department of Agriculture database, which
provides updated information of flavonoid contents
of foods.
We acknowledge some limitations to the study. Having
five case groups and only one control group might have
reduced the power to detect statistically significant
differences between the participants. Moreover, we
defined the potential confounders a priori based on
pre-existing knowledge on their relationship with flavo-
noids and with the outcomes evaluated; however, residual
confounding may still exist. The Italian version of the EPIC
FFQ provides an extensive list of foods with high content
of flavonoids, which allowed us to derive estimates for
all major subclasses. However, the earlier validation study
of the Italian version of the EPIC FFQ showedmodest levels
of agreement in the intakes of macronutrients and some
foods, and has not been validated specifically for flavonoid
intake(28). Finally, we used data from a single FFQ and
assumed that adults maintained relatively stable dietary
habits to investigate disease risk(53).
Overall, the results of the present population-based,
multi-case–control study suggest that intake of flavanones
is negatively associated with the risk of having NAR. No
associations were found between other flavonoids and
the considered outcomes.
Table 3 Unadjusted and adjusted* relative risk ratios (RRR) and 95% confidence intervals of being a respiratory disease case rather than a
control (n 397), according to the intake of flavonoids†, amongadults from theGEIRD (GenesEnvironment Interaction inRespiratoryDiseases)
population-based multi-case–control study in Pavia, Torino, Sassari and Verona, Italy, 2007–2010
Flavonoid intake
(per mg/d increase of 1 SD)
CA (n 159) PA (n 78) CB (n 47) AR (n 167) NAR (n 142)
RRR 95% CI RRR 95% CI RRR 95% CI RRR 95% CI RRR 95% CI
Total flavonoids (unadjusted) 0·98 0·81, 1·18 0·94 0·73, 1·21 0·94 0·69, 1·28 0·93 0·77, 1·12 0·99 0·82, 1·20
Total flavonoids (adjusted) 1·05 0·80, 1·37 0·92 0·65, 1·30 1·12 0·72, 1·73 0·94 0·72, 1·22 1·02 0·77, 1·34
Flavanones (unadjusted) 1·01 0·85, 1·20 0·80 0·60, 1·07 0·81 0·57, 1·16 0·98 0·82, 1·17 0·86 0·69, 1·06
Flavanones (adjusted) 1·09 0·81, 1·45 0·67 0·42, 1·08 0·97 0·52, 1·79 0·88 0·66, 1·19 0·68 0·47, 0·97
Anthocyanins (unadjusted) 0·93 0·77, 1·12 0·93 0·73, 1·19 0·92 0·68, 1·26 0·95 0·79, 1·13 0·96 0·79, 1·15
Anthocyanins (adjusted) 0·83 0·62, 1·11 1·14 0·76, 1·71 0·97 0·62, 1·53 0·93 0·70, 1·25 0·98 0·71, 1·35
Flavan-3-ols (unadjusted) 0·98 0·81, 1·19 0·98 0·76, 1·27 1·05 0·78, 1·41 0·93 0·76, 1·13 1·04 0·86, 1·26
Flavan-3-ols (adjusted) 0·98 0·79, 1·22 0·89 0·66, 1·20 1·08 0·76, 1·54 0·92 0·74, 1·15 1·06 0·86, 1·32
Flavonols (unadjusted) 0·88 0·72, 1·07 0·93 0·72, 1·20 1·20 0·92, 1·56 0·93 0·77, 1·12 0·97 0·80, 1·18
Flavonols (adjusted) 0·81 0·63, 1·06 0·98 0·71, 1·36 1·37 0·97, 1·94 0·88 0·69, 1·13 0·94 0·73, 1·21
Flavones (unadjusted) 1·04 0·87, 1·24 0·94 0·73, 1·21 1·14 0·86, 1·49 0·94 0·78, 1·13 0·96 0·79, 1·16
Flavones (adjusted) 0·93 0·71, 1·22 1·03 0·71, 1·51 1·00 0·69, 1·47 0·81 0·62, 1·07 0·95 0·71, 1·27
Polymers (unadjusted) 0·98 0·82, 1·18 0·96 0·75, 1·23 0·93 0·67, 1·27 0·93 0·77, 1·12 1·01 0·83, 1·22
Polymers (adjusted) 1·08 0·84, 1·39 0·97 0·70, 1·33 1·09 0·72, 1·66 0·98 0·76, 1·26 1·03 0·80, 1·34
Proanthocyanidins (unadjusted) 1·02 0·85, 1·22 0·96 0·75, 1·24 0·95 0·69, 1·30 0·95 0·79, 1·15 1·01 0·83, 1·22
Proanthocyanidins (adjusted) 1·11 0·88, 1·41 0·95 0·69, 1·29 1·05 0·70, 1·58 1·00 0·78, 1·26 1·03 0·81, 1·32
CA, current asthma; PA, past asthma; CB, chronic bronchitis; AR, allergic rhinitis; NAR, non-allergic rhinitis.
*The estimates were adjusted for age, gender, centre, study cohort, BMI, smoking habits, alcohol intake, educational level, total fruit intake, vitamin C intake and total energy
intake.
†Significant results are shown in bold.
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